Published: American Journal of Nephrology
Date:
Authors: Meg J Jardine 1 2 , Kenneth W Mahaffey 3 , Bruce Neal 1 4 5 6 , Rajiv Agarwal 7 , George L Bakris 8 , Barry M Brenner 9 , Scott Bull 10 , Christopher P Cannon 11 , David M Charytan 12 , Dick de Zeeuw 13 , Robert Edwards 10 , Tom Greene 14 , Hiddo J L Heerspink 13 , Adeera Levin 15 , Carol Pollock 16 , David C Wheeler 17 , John Xie 10 , Hong Zhang 18 , Bernard Zinman 19 , Mehul Desai 10 , Vlado Perkovic 1 , CREDENCE study investigators
Abstract:
People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion.